Evidence map›Paper›PMID 37886159›Full record

ArticleBioinformation2023

Multi-epitope vaccine candidate design for dengue virus.

A Dharani, D R Ezhilarasi, G Priyadarsini, P A Abhinand

Open access · hybridAbstract read
In one paragraph

Article in Bioinformation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

A DharaniDepartment of Bioinformatics, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai - 600 116, India.
D R EzhilarasiDepartment of Bioinformatics, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai - 600 116, India.
G PriyadarsiniDepartment of Bioinformatics, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai - 600 116, India.
P A AbhinandDepartment of Bioinformatics, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai - 600 116, India.
Sri Ramachandra Institute of Higher Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue Fever (DF) is a vector-borne neglected viral disease with a high burden in the sub-tropics of Asia and Africa. Aedes aegypti is responsible for 90% of cases in the global burden of disease. The primary goal of the treatment is to eliminate the virus from the bloodstream of affected individuals. A successful dengue vaccine must elicit both neutralizing antibodies and cell-mediated immunity and there is no vaccine to date to prevent DF. A multi-epitope vaccine composed of a series of or overlapping peptides is, therefore, an ideal approach for the prevention and treatment of pathogenic organisms. An immunoinformatics approach was employed to design a theoretical multi-epitope vaccine candidate. This vaccine candidate consists of linear B-cell epitope, TH cells epitope and CTL of reported potential vaccine candidates. These epitopes were linked together with suitable linkers and adjuvant at the N terminal and C terminal. The 3D Structure of the vaccine was modeled, refined and validated using computational tools. Protein-protein docking of vaccine candidates with TLR3 protein results in efficient binding. Immune stimulation of vaccine candidates predicted high levels of IgG and IgM. This candidate vaccine should be validated experimentally using suitable in-vivo and in-vitro studies to use in dengue fever virus elimination programmes.

Indexed as

antibodyantigenDenguedockingepitopeimmune simulationlinkers

Identifiers

PMID37886159
PMCPMC10599669
OpenAlexW4386983120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.